Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

ENLV Sales of Investments

Cash received from selling or redeeming investments.

Enlivex Therapeutics Ltd.NASDAQ: ENLV

Sales of Investments · Q4 FY2025 · quarter ended Dec 2025

Sales of investments growth accelerates

Q4 FY2025 sales of investments of $12M rose 174.2% year over year, ahead of the +11.7% change in trailing-twelve-month sales of investments. Sequentially, it rose 7.2% from the prior quarter. Over 3 fiscal years it compounded at -17.0% a year.

Context

  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +174.2% holds above the trailing-twelve-month pace of +11.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$12M+7.2% QoQ
Last fiscal yearDec 2025
$41.37M+5.4% YoY
LTMDec 2025
$43.78M+11.7% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+174.2%——
1 year+5.4%——
3-year CAGR-17.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
41.37M USD
Year-over-year change
+5.4%
4-year CAGR
-11.6%

Sales of Investments vs competitors

How ENLV compares with its peers on the latest reported figures

  • ENLV's LTM Dec 2025 sales of investments of $43.78M is the largest of the 2 companies compared; the peer median is $0.
ENLV Competitors Peer median
Sales of Investments for ENLV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$43.78M +11.7%-17.0%—
NRXSNeurAxis, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ENLV) $0——0.0%

Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.47M)(31.06M)(29.07M)(15.01M)1.24B
Depreciation & Amortization546K777K835K545K332K
Deferred Income Tax(5.59M)000382.65M
Stock-Based Compensation2.91M2.71M1.95M2.07M1.78M
Change in Working Capital(1.36M)804K(1.82M)(1.22M)815K
Accounts Receivables(1.25M)278K608K433K(3.05M)
Inventory1.25M(278K)000
Accounts Payables442K1.17M(1.12M)(16K)3M
Other Working Capital(1.8M)(364K)(1.31M)(1.64M)869K
Other Non-Cash Items413K2.81M4.58M614K(1.63B)
Operating Cash Flow(17.54M)(23.95M)(23.52M)(13.01M)(10.42M)
Capital Expenditures(1.63M)(8.12M)(236K)(103K)(68K)
Acquisitions (Net)(20.03M)(9.71M)001.38M
Purchases of Investments(104.42M)(1.61M)(26.17M)(32.37M)(24.5M)
Sales of Investments67.63M72.25M301K39.24M41.37M
Other Investing Activities20.03M9.71M133K2.29M0
Investing Cash Flow(38.41M)62.52M(25.97M)9.06M(1.32M)
Debt Repayment00000
Common Stock Issued53.17M150K360K6.45M10.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.81M002K0
Financing Cash Flow60.98M150K360K6.45M10.38M
Effect of Forex Changes(408K)(91K)00(49K)
Net Change in Cash4.62M38.72M(49.13M)2.51M(1.41M)
Free Cash Flow(19.17M)(32.08M)(23.76M)(13.11M)(10.48M)

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Intrinsic Alpha fair value

Locked

Current Price

$4.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.